Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437324 | 0.79 | PTGS2 (0.50) | PTGS2ACHECYP3A4MAPTCA9 | |
| SCHEMBL4054939 | 0.79 | CYP3A4 (0.44) | CYP3A4MAPTALOX5 | |
| SCHEMBL806465 | 0.78 | HTR2A (0.44) | PTGS2ACHECYP3A4MAPTCA9 | |
| SCHEMBL13402430 | 0.75 | HTR2A (0.41) | PTGS2HTR2AHTR2CHTR2B | |
| SCHEMBL13402844 | 0.75 | GAA (0.41) | PTGS2ACHECYP3A4MAPTCA9 | |
| SCHEMBL28207417 | 0.72 | ACHE (0.48) | PTGS2ACHECYP3A4MAPTCA9 | |
| SCHEMBL13402310 | 0.71 | MAPK1 (0.41) | MAPK1 | |
| SCHEMBL5572443 | 0.71 | PTGS2 (0.59) | PTGS2ACHECYP3A4MAPTCA9 | |
| SCHEMBL28127826 | 0.69 | KDM4E (0.52) | PTGS2ACHECYP3A4MAPTCA9 | |
| SCHEMBL14113380 | 0.67 | ALDH1A1 (0.42) | CA9HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754192-B2 | Compositions comprising homogeneously glycosylated erythropoietin | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-06-17 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | PTGS2 2438/4885ACHE 3340/4885CYP3A4 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.